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ABSTRACT Mycosis fungoides (MF) is the most common type of 
cutaneous lymphoma and accounts for approximately 50% of all 
lymphomas arising primarily in the skin. The three types of MF le-
sions are patches, plaques, and tumors, according to which the 
disease is traditionally divided into three clinical stages. The clini-
cal course can be protracted and take years or decades. In the final 
stage, MF evolves to a systemic form of the disease. Nodular pru-
rigo (NP) is still a condition of unknown etiology characterized by 
papulonodular eruption and intense pruritus. Multiple diseases, 
including dermatological, systemic, and psychiatric diseases, have 
been assumed to cause NP. Pruritic skin lesions have been known to 
precede clinically evident B and T cell lymphomas for years. In the 
literature, pruritus and NP have been reported in patients affected 
by systemic Hodgkin and non-Hodgkin lymphomas. Only two cases 
of cutaneous lymphoma as underlying disease in patients with PN 
have been reported in the literature. We report a rare case of a pa-
tient with concomitant non-Hodgkin skin lymphoma – MF and NP. 
Our female patient with a 10-year history of MF stage IIb during the 
last three years had been presenting for regular check-up with itchy, 
newly formed, rarely disseminated nodules 5-8 mm in diameter on 
the forearms and lower legs. Sharply limited erythematosquamous, 
slightly infiltrated foci (as part of MF as the underlying disease) were 
visible on the trunk and extremities. Extracutaneous involvement 
of MF was excluded. We performed a biopsy on a nodule from the 
lower leg to rule out tumor stage MF; the biopsy confirmed NP. We 
conclude that prurigo nodules should not be confused with tumor 
stage MF. NP is a therapeutic challenge for any dermatologist. Any 
underlying diseases should be treated first.
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INTRODUCTION
Pruritic skin lesions have long been known to 
precede clinically evident B and T cell lymphomas. In 
the literature, pruritus and nodular prurigo (NP) have 
been reported in association with systemic Hodgkin 
lymphoma (HL) and non-Hodgkin lymphomas (NHLs) 
(1,2). Mycosis fungoides (MF) is the most common 
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type of cutaneous T cell lymphoma (CTCL) and ac-
counts for approximately 50% of all CTCL. Moreover, 
population-based studies have shown an increas-
ing incidence of MF (3). The cause of MF remains 
unknown. Typically, MF starts as an indolent disease 
progressing from a patch stage through confluent 
plaques to the development of skin tumors. Finally, it 
evolves to a systemic form of the disease. The average 
time of transition from stage I to III is around 12 years. 
One of the hallmarks of MF and Sézary syndrome (SS) 
is pruritus that rarely responds to treatment. Pruri-
tus affects a large proportion of patients with CTCL 
and is significantly more severe in late- than in early-
stage disease and in SS than in MF (4). Recent study 
showed that chemokine (C-C motif ) ligand 1 (CCL1), 
chemokine (C-C motif ) ligand 26 (CCL26), lactate de-
hydrogenase (LDH), and immunoglobulin E (IgE) are 
associated with pruritus in patients with CTCL, while 
nerve growth factor (NGF) is associated with SS. In-
creased dermal nerve fibers, probably induced by 
enhanced NGF expression, may explain the severe 
pruritus frequently seen in patients with SS (5). If 
there are isolated tumors that were not preceded by 
a patch or plaque, other types of T cell lymphomas 
should be taken into consideration. The recommend-
ed diagnostic schemes require histological examina-
tion extended by immunohistochemistry for immu-
nophenotyping of neoplastic cells. The therapeutic 
approach in skin lymphomas is based on histological 
diagnosis and the disease stage evaluated according 
to tumor-node-metastasis-blood (TNMB) classifica-
tion (6). 
NP is a chronic inflammatory dermatosis of un-
known etiology. It causes a papulonodular eruption 
that generates an intense itch. The incidence and 
prevalence of NP are not known. Although the cause 
of NP is unknown, various conditions such as internal 
malignancies, liver and renal failure, and dermatolog-
ical and psychiatric illnesses may induce NP. A broad 
variety of diseases have been reported to underlie NP, 
including nummular eczema, cutaneous mycobacte-
rial infection in NP nodules, atopic dermatitis, HIV 
infection, anemia, gastric Helicobacter pylori infec-
tion, depression, anxiety, lactase deficiency, sorbitol 
intolerance, etc. (7). Several variants of bullous pem-
phigoid, including nodular pemphigoid, and linear 
immunoglobulin A (IgA) disease may mimic or evolve 
from or into NP (8,9). NP is a challenging condition to 
treat. Current first-line agents are topical antipruritics, 
oral antihistamines, and topical, oral, and intralesional 
glucocorticoids. Second-line agents are narrowband 
ultraviolet B (UVB) light therapy (NB-UVB), psoralen 
combined with ultraviolet A (UVA) treatment (PUVA), 
cryotherapy, topical vitamin D3, capsaicin, and tha-
lidomide (10). Except for case reports and case series, 
there are no randomized clinical studies on the treat-
ment of NP. 
Figure 1. Erythematous, slightly infiltrated lesion as 
part of mycosis fungoides (MF) as the underlying dis-
ease and prurigo nodule, on the lower leg.
Figure 2. Multiple prurigo nodules on the lower leg.
Figure 3. Varicose veins and erythematous, slightly 
infiltrated lesions as part of mycosis fungoides (MF) 
as the underlying disease, on the lower leg 
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CASE REPORT
We report a rare case of non-Hodgkin skin lym-
phoma –- MF associated with NP. A 59-year-old Cau-
casian woman with a 10-year history of MF stage IIb 
during the last three years had been presenting for 
regular check-up with itchy, newly formed, rarely 
disseminated nodules of 5-8 mm in diameter on the 
forearms and lower legs (Figure 1, 2). Our patient had 
also had varicose veins of the lower limbs for many 
years (Figure 3). This was unusual, since with varicose 
veins only a single small nodule may be expected. 
Sharply limited erythematosquamous, slightly infil-
trated foci (as part of MF as the underlying disease) 
were visible on the trunk and extremities (Figure 1, 3, 
4, 5). Over the last three years, she had been treated 
for MF with local and oral corticosteroid therapy and 
PUVA therapy (once a year). In order to exclude tu-
mor stage MF, a biopsy was obtained from the nodule 
on the lower leg, and a new diagnosis of NP was es-
tablished (Figure 6). Standard diagnostic procedures 
confirmed that there was no extracutaneous involve-
ment of MF. Although the patient was treated for MF 
with oral corticosteroid and PUVA, which was the 
therapy of choice for both diseases, along with potent 
topical glucocorticoid ointment and antihistamines, 
on a follow-up visit she presented with progression 
and multiple new prurigo nodules. At the same time, 
the patient had achieved almost complete regression 
of lesions of the primary disease, MF. We then started 
to treat prurigo nodules with intralesional corticoste-
roids; an almost complete regression of prurigo nod-
ules and clinical improvement in terms of reduced 
itching were achieved after two applications. 
DISCUSSION
Many conditions have been reported to induce NP. 
The latest retrospective study investigated the distri-
bution of coexisting diseases in a large representative 
consecutive cohort of 108 patients with NP. In 87% of 
patients, diseases underlying NP could be established. 
Monofactorial NP is rare, and the majority of patients 
in this study were classified in the mixed-origin group 
with a combination of two or three co-factors (more 
than one disease was found to be related to induc-
tion and maintenance of pruritus). Nearly half of all 
patients with NP had an atopic predisposition. The 
majority of co-factors in the NP group of mixed ori-
gin were systemic factors, followed by dermatologi-
Figure 5. Mycosis fungoides: many dermal lympho-
cytes are atypical, of larger size and nuclear irregular-
ity, and almost all of them are CD4 positive. There are 
a few atypical larger CD4+ lymphocytes in the epi-
dermis (immunohistochemistry, CD4 ×400).
Figure 6. Nodular prurigo: irregular acanthosis, der-
mal fibrosis, and mononuclear infiltrate in upper der-
mis (hematoxylin and eosin (HE) ×100)
Figure 4. Mycosis fungoides: The epidermis has a 
psoriasiform appearance with acanthosis and is infil-
trated, particularly in the basal layer, by the atypical 
lymphoid cells. The upper dermis contained mostly 
lichenoid infiltratate and minimal perivascular infil-
trate of atypical lymphocytes (hematoxylin and eosin 
(HE) ×200).
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cal, neurological, and psychological factors. Atopic 
diathesis, stasis dermatitis, cutaneous lymphoma, 
allergic contact dermatitis, dermatitis herpetiformis, 
Grover’s disease, and lichen planus were reported as 
underlying dermatological factors in this NP group of 
multifactorial etiology (7). The role of these illnesses 
as precipitants or comorbidities is unclear. They may 
just be a range of conditions that induce a propensity 
to skin irritation and unmask a tendency to localized 
itchiness of the skin. NP can precede clinically evident 
lymphomas by several years (2). 
Systemic NHLs are often accompanied by cutane-
ous manifestations that, according to the study con-
ducted by Carlesimo et al., can be divided into specific 
(macules, papules, nodules, plaques, erythema) and 
non-specific (paraneoplastic pemphigus, generalized 
eczematous-like eruption, acquired ichtyosis, insect 
bite-like reactions, pruritus, erythroderma, granu-
loma annulare, granuloma annulare centrifugum, 
vascular lesions, prurigo nodularis, palmar hyperker-
atosis, urticarial vasculitis, Sweets syndrome, Bazex 
syndrome). In this study, only two patients affected 
by systemic NHL had prurigo nodularis as cutaneous 
manifestation (11). The diversity of the clinical mani-
festations could be explained by the associated alter-
ation in immune regulation that is typical of patients 
affected by systemic lymphomas because lympho-
cytes are the main effectors of our immune response 
(12). In our patient, NP developed some ten years 
after establishment of the diagnosis of MF. Although 
these are common diagnoses, a case of MF associated 
with NP was, to our knowledge, not reported in the 
literature to date. NP is a benign condition. However, 
it can cause severe functional impairment and mor-
bidity due to poor control of the itching/scratching 
and psychological symptoms. Symptoms of itch-
ing and the typical skin lesions are usually enough 
to establish the diagnosis of NP, but in our patient 
skin biopsy was performed to exclude MF progres-
sion. One of the hallmarks of MF and NP is pruritus 
that rarely responds to treatment. The itching of NP 
was very distressing for our patient, much worse than 
that of MF and severe enough to disturb both sleep 
at night and daytime activities. In our patient, NP 
predominantly affected the extensor aspects of the 
lower limbs. It is known that calcitonin gene-related 
peptide and substance P immunoreactive nerves are 
markedly increased in number and activity in the skin 
of patients with NP, compared with normal skin (13). 
Whether this represents a causative etiology or arises 
as a result of chronic scratching and skin irritation is 
not known. One study found hypoplasia of epider-
mal sensory nerves in the skin of patients with NP 
even in areas where pruritus was not a problem (14). 
Often, combinations of several medications or physi-
cal modalities may be used in an attempt to control 
this process. Although our patient was treated for MF 
with oral corticosteroid and PUVA along with potent 
topical glucocorticoid ointment and antihistamines, 
there was no improvement in the itchiness caused by 
NP and in attempts to soften and smooth out the firm 
nodules. In spite of the therapy our patient presented 
with progression and multiple new prurigo nodules 
on the arms and legs, but almost complete regression 
of MF lesions. We used an intralesional corticosteroid, 
triamcinolone acetonide, in concentrations of 2.5 
mg/mL every 3 weeks and achieved almost complete 
regression of prurigo nodules and reduced itching af-
ter two applications. 
CONCLUSION
We conclude that prurigo nodules should not be 
confused with cutaneous lymphoma or MF progres-
sion. Skin biopsy may be performed to rule out malig-
nant process. NP is difficult to manage, posing a chal-
lenge for any dermatologist. Any underlying diseases 
should be treated first.
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